This inventor holds 1 USPTO granted patent and 3 published patent applications. Top assignee: Novartis Ag. Active years: 2025.
Company Filing History:
Years Active: 2025
Title: Innovations of Lukas Roth in Hidradenitis Suppurativa Treatment
Introduction
Lukas Roth is a notable inventor based in Riehen, Switzerland. He has made significant contributions to the field of medical treatments, particularly in the area of hidradenitis suppurativa. His innovative work focuses on the use of anti-CD40 antibodies, which have the potential to transform treatment regimens for this challenging condition.
Latest Patents
Lukas Roth holds a patent for "Anti-CD40 antibodies for use in treatment of hidradenitis suppurativa." This patent encompasses various methods, treatment regimens, uses, kits, and therapies aimed at treating hidradenitis suppurativa through the application of CD40 antagonists, specifically anti-CD40 antibodies. This innovative approach represents a significant advancement in the therapeutic options available for patients suffering from this condition. He has 1 patent to his name.
Career Highlights
Lukas Roth is associated with Novartis AG, a leading global healthcare company. His work at Novartis has allowed him to collaborate with other talented professionals in the field, contributing to groundbreaking research and development in medical treatments.
Collaborations
Lukas has worked alongside notable colleagues such as Pascal Espie and Christian Loesche. Their combined expertise has fostered an environment of innovation and progress in the treatment of hidradenitis suppurativa.
Conclusion
Lukas Roth's contributions to the field of medical treatment, particularly through his patent on anti-CD40 antibodies, highlight his role as an influential inventor. His work continues to pave the way for new therapeutic options for patients with hidradenitis suppurativa.